Unanswered questions in PSMA-targeted radionuclide therapy

There are many areas of uncertainty surrounding prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT), which must be investigated further. Scott T. Tagawa, MD, MS, Weill Cornell Medical College, New York Presbyterian Hospital, NY, discusses some of the most pertinent issues, including the safety and efficacy of using PSMA-TRT as an earlier line of therapy, potentially in combination with cabazitaxel. Questions also remain unanswered vis-a-vis the optimal patient population to receive PSMA-TRT treatment, understanding why PSMA-positive patients identified through PSMA-PET may respond better to treatment with PSMA-TRT, as well as the optimal schedule and dosage. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.